Bay Colony Advisory Group Inc d b a Bay Colony Advisors Makes New Investment in Inotiv, Inc. (NASDAQ:NOTV)

Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in Inotiv, Inc. (NASDAQ:NOTV) during the fourth quarter, Holdings Channel.com reports. The institutional investor bought 14,397 shares of the company’s stock, valued at approximately $60,000.

A number of other institutional investors have also bought and sold shares of NOTV. AlphaCentric Advisors LLC purchased a new position in Inotiv in the 4th quarter worth approximately $163,000. Calamos Advisors LLC purchased a new position in Inotiv in the 4th quarter worth approximately $275,000. Geode Capital Management LLC lifted its stake in Inotiv by 7.7% in the 3rd quarter. Geode Capital Management LLC now owns 250,895 shares of the company’s stock worth $427,000 after purchasing an additional 18,039 shares in the last quarter. Nkcfo LLC purchased a new position in Inotiv in the 4th quarter worth approximately $476,000. Finally, Thurston Springer Miller Herd & Titak Inc. lifted its stake in Inotiv by 612.5% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 127,257 shares of the company’s stock worth $527,000 after purchasing an additional 109,397 shares in the last quarter. 18.17% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Robert Jr. Leasure sold 22,700 shares of Inotiv stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $4.15, for a total value of $94,205.00. Following the completion of the sale, the chief executive officer now owns 1,030,209 shares in the company, valued at approximately $4,275,367.35. This trade represents a 2.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Nigel Brown bought 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The stock was bought at an average price of $4.26 per share, with a total value of $31,950.00. Following the acquisition, the director now directly owns 65,537 shares in the company, valued at $279,187.62. The trade was a 12.92 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 61,029 shares of company stock valued at $274,448 and have sold 108,311 shares valued at $425,330. Corporate insiders own 7.80% of the company’s stock.

Inotiv Stock Down 1.5 %

NOTV stock opened at $2.62 on Friday. The firm has a market cap of $88.34 million, a PE ratio of -0.57 and a beta of 3.77. The company has a debt-to-equity ratio of 2.31, a quick ratio of 1.28 and a current ratio of 1.57. The firm’s 50 day moving average price is $4.04 and its 200-day moving average price is $3.07. Inotiv, Inc. has a one year low of $1.23 and a one year high of $11.42.

Inotiv (NASDAQ:NOTV) last released its quarterly earnings results on Wednesday, February 5th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.10). Inotiv had a negative net margin of 25.40% and a negative return on equity of 15.41%. On average, equities research analysts anticipate that Inotiv, Inc. will post -0.79 EPS for the current year.

Inotiv Company Profile

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.